Evidence map›Paper›PMID 34197866›Full record

ArticleBiochimie2021

Dual-targeted anti-CMV/anti-HIV-1 heterodimers.

Anastasia L Khandazhinskaya, Vincenzo Mercurio, Anna A Maslova, Rogers Alberto Ñahui Palomino, Mikhail S Novikov, Elena S Matyugina, Maria P Paramonova, Marina K Kukhanova, Natalya E Fedorova, Kirill I Yurlov and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochimie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Anastasia L KhandazhinskayaEngelhardt Institute of Molecular Biology, Vavilova Str., 32, Moscow, 119991, Russia. Electronic address: khandazhinskaya@bk.ru.
Vincenzo MercurioEunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA.
Anna A MaslovaEngelhardt Institute of Molecular Biology, Vavilova Str., 32, Moscow, 119991, Russia.
Rogers Alberto Ñahui PalominoEunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA.
Mikhail S NovikovDepartment of Pharmaceutical & Toxicological Chemistry, Volgograd State Medical University, Pavshikh Bortsov Sq., 1, Volgograd, 400131, Russia.
Elena S MatyuginaEngelhardt Institute of Molecular Biology, Vavilova Str., 32, Moscow, 119991, Russia.
Maria P ParamonovaDepartment of Pharmaceutical & Toxicological Chemistry, Volgograd State Medical University, Pavshikh Bortsov Sq., 1, Volgograd, 400131, Russia.
Marina K KukhanovaEngelhardt Institute of Molecular Biology, Vavilova Str., 32, Moscow, 119991, Russia.
Natalya E FedorovaIvanovsky Institute of Virology, Gamaleya National Research Center of Epidemiology and Microbiology, Gamaleya Str., 16, Moscow, 123098, Russia.
Kirill I YurlovIvanovsky Institute of Virology, Gamaleya National Research Center of Epidemiology and Microbiology, Gamaleya Str., 16, Moscow, 123098, Russia.
Alla A KushchIvanovsky Institute of Virology, Gamaleya National Research Center of Epidemiology and Microbiology, Gamaleya Str., 16, Moscow, 123098, Russia.
Olga TarasovaInstitute of Biomedical Chemistry, Pogodinskaya Str., 10, Moscow, 119121, Russia.
Leonid MargolisEunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA.
Sergey N KochetkovEngelhardt Institute of Molecular Biology, Vavilova Str., 32, Moscow, 119991, Russia.
Christophe VanpouilleEunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: vanpouic@mail.nih.gov.
Engelhardt Institute of Molecular Biology · RUNational Institutes of Health · USVolgograd State Medical University · RUInstitute of Biomedical Chemistry · RU

Funding

Viral transmission and pathogenesis in human tissuesZIAHD008968 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI MARGOLIS, LEONID B. · 2018 to 2023
$12.2M
Intramural NIH HHS Z99 HD999999
6 · The paper itself

Abstract

Despite the development of efficient anti-human immunodeficiency virus-1 (HIV-1) therapy, HIV-1 associated pathogens remain a major clinical problem. Human cytomegalovirus (CMV) is among the most common HIV-1 copathogens and one of the main causes of persistent immune activation associated with dysregulation of the immune system, cerebrovascular and cardiovascular pathologies, and premature aging. Here, we report on the development of dual-targeted drugs with activity against both HIV-1 and CMV. We synthesized seven compounds that constitute conjugates of molecules that suppress both pathogens. We showed that all seven compounds exhibit low cytotoxicity and efficiently inhibited both viruses in cell lines. Furthermore, we chose a representative compound and demonstrated that it efficiently suppressed replication of HIV-1 and CMV in human lymphoid tissue ex vivo coinfected with both viruses. Further development of such compounds may lead to the development of dual-targeted anti-CMV/HIV-1 drugs.

Indexed as

Antiviral AgentsAnimalsCell LineCoinfectionCytomegalovirusCytomegalovirus InfectionsHIV-1HIV InfectionsHumansSwineAntiviral AgentsCMVHeterodimersHIV-1Human tissuesViral diseases

Identifiers

PMID34197866
PMCPMC8458242
OpenAlexW3177059142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.